This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
The evolution of treatment options over the past 20 years has provided for a normal life expectancy for most patients with chronic myeloid leukemia. Currently approved tyrosine kinase inhibitors mainly differ in potency and side effect profile. Flumatinib goes for deep responses and good tolerability.
See related article by Zhang et al., p. 70
Footnotes
Clin Cancer Res 2021;27:3–4
- Received October 2, 2020.
- Revision received October 10, 2020.
- Accepted October 23, 2020.
- Published first October 27, 2020.
- ©2020 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
January 2021
Volume 27, Issue 1
Volume 27, Issue 1
New Drug for Chronic Myeloid Leukemia Might Stimulate the Market
Jump to section
Advertisement